These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

538 related articles for article (PubMed ID: 30777447)

  • 1. KEYNOTE-585: Phase III study of perioperative chemotherapy with or without pembrolizumab for gastric cancer.
    Bang YJ; Van Cutsem E; Fuchs CS; Ohtsu A; Tabernero J; Ilson DH; Hyung WJ; Strong VE; Goetze TO; Yoshikawa T; Tang LH; Hwang PMT; Webb N; Adelberg D; Shitara K
    Future Oncol; 2019 Mar; 15(9):943-952. PubMed ID: 30777447
    [TBL] [Abstract][Full Text] [Related]  

  • 2. KEYNOTE-859: a Phase III study of pembrolizumab plus chemotherapy in gastric/gastroesophageal junction adenocarcinoma.
    Tabernero J; Bang YJ; Van Cutsem E; Fuchs CS; Janjigian YY; Bhagia P; Li K; Adelberg D; Qin SK
    Future Oncol; 2021 Aug; 17(22):2847-2855. PubMed ID: 33975465
    [TBL] [Abstract][Full Text] [Related]  

  • 3. First-line pembrolizumab/placebo plus trastuzumab and chemotherapy in HER2-positive advanced gastric cancer: KEYNOTE-811.
    Chung HC; Bang YJ; S Fuchs C; Qin SK; Satoh T; Shitara K; Tabernero J; Van Cutsem E; Alsina M; Cao ZA; Lu J; Bhagia P; Shih CS; Janjigian YY
    Future Oncol; 2021 Feb; 17(5):491-501. PubMed ID: 33167735
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Study protocol of a multicenter phase III randomized controlled trial investigating the efficiency of the combination of neoadjuvant chemotherapy (NAC) and neoadjuvant laparoscopic intraperitoneal hyperthermic chemotherapy (NLHIPEC) followed by R0 gastrectomy with intraoperative HIPEC for advanced gastric cancer (AGC): dragon II trial.
    Beeharry MK; Ni ZT; Yang ZY; Zheng YN; Feng RH; Liu WT; Yan C; Yao XX; Li C; Yan M; Zhu ZG
    BMC Cancer; 2020 Mar; 20(1):224. PubMed ID: 32183736
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Assessment of Pembrolizumab Therapy for the Treatment of Microsatellite Instability-High Gastric or Gastroesophageal Junction Cancer Among Patients in the KEYNOTE-059, KEYNOTE-061, and KEYNOTE-062 Clinical Trials.
    Chao J; Fuchs CS; Shitara K; Tabernero J; Muro K; Van Cutsem E; Bang YJ; De Vita F; Landers G; Yen CJ; Chau I; Elme A; Lee J; Özgüroglu M; Catenacci D; Yoon HH; Chen E; Adelberg D; Shih CS; Shah S; Bhagia P; Wainberg ZA
    JAMA Oncol; 2021 Jun; 7(6):895-902. PubMed ID: 33792646
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Perioperative pembrolizumab therapy in muscle-invasive bladder cancer: Phase III KEYNOTE-866 and KEYNOTE-905/EV-303.
    Galsky MD; Hoimes CJ; Necchi A; Shore N; Witjes JA; Steinberg G; Bedke J; Nishiyama H; Fang X; Kataria R; Sbar E; Jia X; Siefker-Radtke A
    Future Oncol; 2021 Aug; 17(24):3137-3150. PubMed ID: 34008425
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MATTERHORN: phase III study of durvalumab plus FLOT chemotherapy in resectable gastric/gastroesophageal junction cancer.
    Janjigian YY; Van Cutsem E; Muro K; Wainberg Z; Al-Batran SE; Hyung WJ; Molena D; Marcovitz M; Ruscica D; Robbins SH; Negro A; Tabernero J
    Future Oncol; 2022 Jun; 18(20):2465-2473. PubMed ID: 35535555
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phase II study of neoadjuvant docetaxel, oxaliplatin, and S-1 (DOS) chemotherapy followed by surgery and adjuvant S-1 chemotherapy in potentially resectable gastric or gastroesophageal junction adenocarcinoma.
    Park I; Ryu MH; Choi YH; Kang HJ; Yook JH; Park YS; Kim HJ; Jung HY; Lee GH; Kim KC; Kim BS; Kang YK
    Cancer Chemother Pharmacol; 2013 Oct; 72(4):815-23. PubMed ID: 23921575
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Perioperative chemotherapy for resectable gastroesophageal cancer: a single-center experience.
    Molina R; Lamarca A; Martínez-Amores B; Gutiérrez A; Blázquez A; López A; Granell J; Álvarez-Mon M
    Eur J Surg Oncol; 2013 Aug; 39(8):814-22. PubMed ID: 23755989
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adjuvant therapy for locally advanced gastric cancer.
    Aoyama T; Yoshikawa T
    Surg Today; 2017 Nov; 47(11):1295-1302. PubMed ID: 28251375
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Advances in the treatment of gastric cancer.
    Ilson DH
    Curr Opin Gastroenterol; 2018 Nov; 34(6):465-468. PubMed ID: 30303856
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CRITICS-II: a multicentre randomised phase II trial of neo-adjuvant chemotherapy followed by surgery versus neo-adjuvant chemotherapy and subsequent chemoradiotherapy followed by surgery versus neo-adjuvant chemoradiotherapy followed by surgery in resectable gastric cancer.
    Slagter AE; Jansen EPM; van Laarhoven HWM; van Sandick JW; van Grieken NCT; Sikorska K; Cats A; Muller-Timmermans P; Hulshof MCCM; Boot H; Los M; Beerepoot LV; Peters FPJ; Hospers GAP; van Etten B; Hartgrink HH; van Berge Henegouwen MI; Nieuwenhuijzen GAP; van Hillegersberg R; van der Peet DL; Grabsch HI; Verheij M
    BMC Cancer; 2018 Sep; 18(1):877. PubMed ID: 30200910
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of ypT, ypN, and Adjuvant Therapy on Survival in Gastric Cancer Patients Treated with Perioperative Chemotherapy and Radical Surgery.
    Coimbra FJF; de Jesus VHF; Ribeiro HSC; Diniz AL; de Godoy AL; de Farias IC; Felismino T; Mello CAL; Almeida MF; Begnami MDFS; Dias-Neto E; Riechelmann RSP; da Costa WL
    Ann Surg Oncol; 2019 Oct; 26(11):3618-3626. PubMed ID: 31222685
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The UK NCRI MAGIC trial of perioperative chemotherapy in resectable gastric cancer: implications for clinical practice.
    Chua YJ; Cunningham D
    Ann Surg Oncol; 2007 Oct; 14(10):2687-90. PubMed ID: 17653804
    [No Abstract]   [Full Text] [Related]  

  • 15. Perioperative chemotherapy versus adjuvant chemotherapy strategies in resectable gastric and gastroesophageal cancer: A Markov decision analysis.
    Choi M; Ishizawa S; Kraemer D; Sasson A; Feinberg E
    Eur J Surg Oncol; 2022 Feb; 48(2):403-410. PubMed ID: 34446344
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Perioperative chemotherapy versus postoperative chemoradiotherapy in patients with resectable gastric/gastroesophageal junction adenocarcinomas: A survival analysis of 5058 patients.
    Fitzgerald TL; Efird JT; Bellamy N; Russo SM; Jindal C; Mosquera C; Holliday EG; Biswas T
    Cancer; 2017 Aug; 123(15):2909-2917. PubMed ID: 28386965
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Level I evidence in support of perioperative chemotherapy for operable gastric cancer: sufficient for wide clinical use?
    Briasoulis E; Fatouros M; Roukos DH
    Ann Surg Oncol; 2007 Oct; 14(10):2691-5. PubMed ID: 17653806
    [No Abstract]   [Full Text] [Related]  

  • 18. Efficacy of Pembrolizumab Monotherapy in Japanese Patients with Advanced Gastric or Gastroesophageal Junction Cancer.
    Muro K; Shitara K; Yamaguchi K; Yoshikawa T; Satake H; Hara H; Sugimoto N; Machida N; Goto M; Kawakami H; Amagai K; Omuro Y; Esaki T; Hironaka S; Nishina T; Komatsu Y; Matsubara H; Shiratori S; Han S; Satoh T; Ohtsu A
    J Gastrointest Cancer; 2023 Sep; 54(3):951-961. PubMed ID: 37037952
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neoadjuvant chemotherapy, surgery, and adjuvant intraperitoneal chemotherapy in patients with locally advanced gastric or gastroesophageal junction carcinoma: a phase II study.
    Newman E; Potmesil M; Ryan T; Marcus S; Hiotis S; Yee H; Norwood B; Wendell M; Muggia F; Hochster H
    Semin Oncol; 2005 Dec; 32(6 Suppl 9):S97-100. PubMed ID: 16399443
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chemotherapy versus chemoradiotherapy after surgery and preoperative chemotherapy for resectable gastric cancer (CRITICS): an international, open-label, randomised phase 3 trial.
    Cats A; Jansen EPM; van Grieken NCT; Sikorska K; Lind P; Nordsmark M; Meershoek-Klein Kranenbarg E; Boot H; Trip AK; Swellengrebel HAM; van Laarhoven HWM; Putter H; van Sandick JW; van Berge Henegouwen MI; Hartgrink HH; van Tinteren H; van de Velde CJH; Verheij M;
    Lancet Oncol; 2018 May; 19(5):616-628. PubMed ID: 29650363
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.